DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews

被引：0
|
作者：
Juan Ling
Long Ge
Ding-hua Zhang
Yong-feng Wang
Zhuo-lin Xie
Jin-hui Tian
Xiao-hui Xiao
Ke-hu Yang
机构：
[1] Lanzhou University,School of Basic Medical Sciences, Evidence
[2] Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province,Based Medicine Center
[3] Lanzhou University,Chinese GRADE Center
[4] WHO Collaborating Center for Guideline Implementation and Knowledge Translation,School of Basic Medical Sciences
[5] The First Clinical Medical College of Lanzhou University,Department of Endocrinology
[6] Gansu University of Traditional Chinese Medicine,undefined
[7] Gansu University of Traditional Chinese Medicine,undefined
[8] Gansu Province Hospital of Traditional Chinese Medicine,undefined
[9] Gansu Provincial People’s Hospital,undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Dipeptidyl peptidase 4 inhibitors; Systematic reviews; Type 2 diabetes mellitus; AMSTAR; GRADE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7 / 27
页数：20
相关论文
共 50 条
  • [11] An update on DPP-4 inhibitors in the management of type 2 diabetes
    Cahn, Avivit
    Cernea, Simona
    Raz, Itamar
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 409 - 419
  • [12] Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
    Giorgio Sesti
    Angelo Avogaro
    Sara Belcastro
    Benedetta Maria Bonora
    Marina Croci
    Giuseppe Daniele
    Marco Dauriz
    Francesco Dotta
    Caterina Formichi
    Simona Frontoni
    Cecilia Invitti
    Emanuela Orsi
    Fabiana Picconi
    Veronica Resi
    Enzo Bonora
    Francesco Purrello
    Acta Diabetologica, 2019, 56 : 605 - 617
  • [13] THE PLACEMENT OF DPP-4 INHIBITORS IN CLINICAL PRACTICE RECOMMENDATIONS FOR THE TREATMENT OF TYPE 2 DIABETES
    Davidson, Jaime A.
    ENDOCRINE PRACTICE, 2013, 19 (06) : 1050 - 1061
  • [14] Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
    Sesti, Giorgio
    Avogaro, Angelo
    Belcastro, Sara
    Bonora, Benedetta Maria
    Croci, Marina
    Daniele, Giuseppe
    Dauriz, Marco
    Dotta, Francesco
    Formichi, Caterina
    Frontoni, Simona
    Invitti, Cecilia
    Orsi, Emanuela
    Picconi, Fabiana
    Resi, Veronica
    Bonora, Enzo
    Purrello, Francesco
    ACTA DIABETOLOGICA, 2019, 56 (06) : 605 - 617
  • [15] Effects of DPP-4 Inhibitors on Cardiovascular System in Type 2 Diabetes
    Ohno, Yasuhiro
    Tanaka, Yoichi
    Fujimoto, Mika
    Maruyama, Yasunori
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [16] DPP-4 inhibitors and their potential role in the management of type 2 diabetes
    Barnett, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) : 1454 - 1470
  • [17] Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
    Gallwitz, Baptist
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 1 - 9
  • [18] Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
    Ahren, Bo
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 : 31 - 41
  • [19] Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
    Kishimoto, Miyako
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 187 - 195
  • [20] Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
    Du, Zouxi
    Lu, Tingting
    Gao, Mingdong
    Tian, Limin
    ACTA DIABETOLOGICA, 2022, 59 (12) : 1539 - 1549
12345